Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1994 1
1995 1
1996 3
1997 3
1998 4
1999 14
2000 19
2001 23
2002 17
2003 23
2004 18
2005 33
2006 62
2007 52
2008 42
2009 43
2010 42
2011 36
2012 52
2013 45
2014 40
2015 54
2016 51
2017 50
2018 52
2019 55
2020 59
Text availability
Article attribute
Article type
Publication date

Search Results

817 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic herpes simplex virus and immunotherapy.
Ma W, He H, Wang H. Ma W, et al. BMC Immunol. 2018 Dec 18;19(1):40. doi: 10.1186/s12865-018-0281-9. BMC Immunol. 2018. PMID: 30563466 Free PMC article. Review.
BACKGROUND: Oncolytic viruses have been proposed to be employed as a potential treatment of cancer. Well targeted, they will serve the purpose of cracking tumor cells without causing damage to normal cells. In this category of oncolytic viral drugs human pathogens …
BACKGROUND: Oncolytic viruses have been proposed to be employed as a potential treatment of cancer. Well targeted, they will serve th …
Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H, Hamada H, Nakano K, Kwon H, Tahara H, Cohen JB, Glorioso JC. Uchida H, et al. Curr Cancer Drug Targets. 2018;18(2):162-170. doi: 10.2174/1568009617666170206105855. Curr Cancer Drug Targets. 2018. PMID: 28176649 Review.
Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the iden
Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cell
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D, Martuza RL, Rabkin SD. Saha D, et al. Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009. Immunotherapy. 2018. PMID: 30008259 Free PMC article.
Oncolytic viruses, such as oncolytic herpes simplex virus (oHSV), are a new class of cancer therapeutic, which selectively replicate and kill cancer cells, while inducing an inflammatory microenvironment, immunovirotherapy. ...
Oncolytic viruses, such as oncolytic herpes simplex virus (oHSV), are a new class of cancer therapeutic, which s
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.
Totsch SK, Schlappi C, Kang KD, Ishizuka AS, Lynn GM, Fox B, Beierle EA, Whitley RJ, Markert JM, Gillespie GY, Bernstock JD, Friedman GK. Totsch SK, et al. Oncogene. 2019 Aug;38(34):6159-6171. doi: 10.1038/s41388-019-0870-y. Epub 2019 Jul 9. Oncogene. 2019. PMID: 31289361 Free PMC article. Review.
Accordingly, novel, targeted therapeutics for neoplasms of the CNS, such as immunotherapy with oncolytic engineered herpes simplex virus (HSV) therapy, are urgently warranted. ...
Accordingly, novel, targeted therapeutics for neoplasms of the CNS, such as immunotherapy with oncolytic engineered herpes
Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins.
Liu XQ, Xin HY, Lyu YN, Ma ZW, Peng XC, Xiang Y, Wang YY, Wu ZJ, Cheng JT, Ji JF, Zhong JX, Ren BX, Wang XW, Xin HW. Liu XQ, et al. Drug Deliv. 2018 Nov;25(1):1950-1962. doi: 10.1080/10717544.2018.1534895. Drug Deliv. 2018. PMID: 30799657 Free PMC article. Review.
Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. ...
Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tum
Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
Hua L, Wakimoto H. Hua L, et al. Expert Opin Biol Ther. 2019 Aug;19(8):845-854. doi: 10.1080/14712598.2019.1614557. Epub 2019 May 13. Expert Opin Biol Ther. 2019. PMID: 31046478 Review.
INTRODUCTION: With the approval of talimogene laherparepvec (T-VEC) for advanced malignant melanoma, virotherapy using oncolytic herpes simplex virus (oHSV) is now emerging as a viable therapeutic option for cancer patients, including malignant gliomas. ...
INTRODUCTION: With the approval of talimogene laherparepvec (T-VEC) for advanced malignant melanoma, virotherapy using oncolytic h
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.
Sanchala DS, Bhatt LK, Prabhavalkar KS. Sanchala DS, et al. Front Pharmacol. 2017 May 16;8:270. doi: 10.3389/fphar.2017.00270. eCollection 2017. Front Pharmacol. 2017. PMID: 28559846 Free PMC article. Review.
Oncolytic viral therapy for treating cancer with herpes simplex virus-1 has been of particular interest owing to its range of benefits like: (a) large genome and power to infiltrate in the tumor, (b) easy access to manipulation with the flexibility to insert
Oncolytic viral therapy for treating cancer with herpes simplex virus-1 has been of particular interest owing to its ra
Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer.
Woo Y, Reid V, Kelly KJ, Carlson D, Yu Z, Fong Y. Woo Y, et al. Mol Ther Oncolytics. 2019 Dec 6;16:1-6. doi: 10.1016/j.omto.2019.11.003. eCollection 2020 Mar 27. Mol Ther Oncolytics. 2019. PMID: 31909180 Free PMC article.
Previously, we have shown that NV1066, an oncolytic herpes simplex-1 virus encoding enhanced green fluorescent protein, selectively infects, replicates in, and kills various cancer types. ...Results indicate that infectivity might be dependent on the herpe
Previously, we have shown that NV1066, an oncolytic herpes simplex-1 virus encoding enhanced green fluorescent protein, …
Oncolytic herpes simplex virus interactions with the host immune system.
Saha D, Wakimoto H, Rabkin SD. Saha D, et al. Curr Opin Virol. 2016 Dec;21:26-34. doi: 10.1016/j.coviro.2016.07.007. Epub 2016 Aug 3. Curr Opin Virol. 2016. PMID: 27497296 Free PMC article. Review.
Oncolytic viruses (OVs), like oncolytic herpes simplex virus (oHSV), are genetically engineered to selectively replicate in and kill cancer cells, while sparing normal cells. ...
Oncolytic viruses (OVs), like oncolytic herpes simplex virus (oHSV), are genetically engineered to selectively r
Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, Gatta V. Campadelli-Fiume G, et al. Viruses. 2016 Feb 26;8(3):63. doi: 10.3390/v8030063. Viruses. 2016. PMID: 26927159 Free PMC article. Review.
Most of the oncolytic herpes simplex viruses (HSVs) exhibit a high safety profile achieved through attenuation. They carry defects in virulence proteins that antagonize host cell response to the virus, including innate response, apoptosis, authophagy, and dep …
Most of the oncolytic herpes simplex viruses (HSVs) exhibit a high safety profile achieved through attenuation. They ca …
817 results
Jump to page
Feedback